• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful Treatment of Erythrodermic Atopic Dermatitis with Dupilumab in a 5-Year-Old Girl: A Case Report with Review of Literature.

作者信息

Agarwal Akash, Dhar Sandipan, Panda Maitreyee, Mishra Bishwajit

机构信息

Department of Dermatology, IMS and SUM Hospital, Bhubaneswar, Odisha, India.

Department of Paediatric Dermatology, Institute of Child Health, Kolkata, West Bengal, India.

出版信息

Indian J Dermatol. 2022 Sep-Oct;67(5):597-600. doi: 10.4103/ijd.ijd_1044_21.

DOI:10.4103/ijd.ijd_1044_21
PMID:36865877
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9971745/
Abstract
摘要

相似文献

1
Successful Treatment of Erythrodermic Atopic Dermatitis with Dupilumab in a 5-Year-Old Girl: A Case Report with Review of Literature.度普利尤单抗成功治疗一名5岁女童的红皮病型特应性皮炎：病例报告并文献复习
Indian J Dermatol. 2022 Sep-Oct;67(5):597-600. doi: 10.4103/ijd.ijd_1044_21.
2
Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials.度普利尤单抗治疗红皮病型特应性皮炎患者的疗效和安全性：6 项随机临床试验的事后分析。
JAMA Dermatol. 2023 Mar 1;159(3):255-266. doi: 10.1001/jamadermatol.2022.6192.
3
Atopic Dermatitis Treated Safely with Dupilumab during Pregnancy: A Case Report and Review of the Literature.孕期使用度普利尤单抗安全治疗特应性皮炎：一例报告及文献综述
Case Rep Dermatol. 2021 May 4;13(2):248-256. doi: 10.1159/000515246. eCollection 2021 May-Aug.
4
Angioedema: A potential complication of dupilumab in atopic dermatitis.血管性水肿：度普利尤单抗治疗特应性皮炎时的一种潜在并发症。
Pediatr Dermatol. 2021 Jan;38(1):237-238. doi: 10.1111/pde.14434. Epub 2020 Oct 25.
5
Atopic Dermatitis with Multiple Comorbidities Treated with Dupilumab. A Case Report and Review of the Literature Regarding the Safety of Dupilumab.使用度普利尤单抗治疗的伴有多种合并症的特应性皮炎。一例病例报告及关于度普利尤单抗安全性的文献综述
Life (Basel). 2022 Oct 21;12(10):1670. doi: 10.3390/life12101670.
6
Dupilumab-associated cicatrizing ocular disease.度普利尤单抗相关的瘢痕性眼病。
Am J Ophthalmol Case Rep. 2022 Apr 9;26:101528. doi: 10.1016/j.ajoc.2022.101528. eCollection 2022 Jun.
7
Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.度普利尤单抗为中度至重度特应性皮炎成人患者提供快速且持续的具有临床意义的缓解。
Acta Derm Venereol. 2021 Nov 10;101(11):adv00585. doi: 10.2340/actadv.v101.307.
8
No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.在长达 4 年的时间里，接受度普利尤单抗治疗的中重度特应性皮炎成人患者的总体感染风险没有增加。
Adv Ther. 2023 Jan;40(1):367-380. doi: 10.1007/s12325-022-02322-y. Epub 2022 Nov 1.
9
Development of systemic lupus erythematosus after dupilumab treatment in a case of atopic dermatitis.在一例特应性皮炎患者中，使用度普利尤单抗治疗后发生系统性红斑狼疮。
J Dermatol. 2022 May;49(5):556-559. doi: 10.1111/1346-8138.16322. Epub 2022 Feb 27.
10
Dupilumab for Atopic Dermatitis, a Possible Risk Factor of Juvenile Ischemic Stroke: A Case Report.度普利尤单抗治疗特应性皮炎致青年缺血性脑卒中：1 例报告。
J Stroke Cerebrovasc Dis. 2020 Jun;29(6):104763. doi: 10.1016/j.jstrokecerebrovasdis.2020.104763. Epub 2020 Apr 4.

本文引用的文献

1
Off-label use of dupilumab for the treatment of moderate to severe atopic dermatitis in children aged below 6 years of age: a case series.度普利尤单抗在6岁以下儿童中用于治疗中度至重度特应性皮炎的超说明书用药：病例系列
Clin Exp Dermatol. 2022 Feb;47(2):423-425. doi: 10.1111/ced.14925. Epub 2021 Oct 19.
2
Real-World Effectiveness and Safety of Dupilumab for the Treatment of Moderate to Severe Atopic Dermatitis in Indian Patients: A Multi Centric Retrospective Study.度普利尤单抗治疗印度中度至重度特应性皮炎患者的真实世界有效性和安全性：一项多中心回顾性研究
Indian J Dermatol. 2021 May-Jun;66(3):297-301. doi: 10.4103/ijd.ijd_860_20.
3
Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic.
度普利尤单抗治疗中度至重度特应性皮炎青少年患者：COVID-19大流行期间的32周真实世界经验
Clin Exp Dermatol. 2022 Jan;47(1):165-167. doi: 10.1111/ced.14862. Epub 2021 Aug 24.
4
Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use.在一项针对未控制的特应性皮炎青少年的3期试验中，度普利尤单抗显示出显著的临床益处，无论之前是否使用过全身免疫抑制剂。
Acta Derm Venereol. 2021 Jul 15;101(7):adv00504. doi: 10.2340/00015555-3848.
5
Dupilumab for children and adolescents with atopic dermatitis: An Asian perspective.达必妥治疗特应性皮炎患儿和青少年患者：亚洲视角。
Dermatol Ther. 2021 May;34(3):e14933. doi: 10.1111/dth.14933. Epub 2021 Mar 16.
6
A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy.一项 2 期、开放标签研究，评估单剂量度普利尤单抗在 6 个月至<6 岁患有严重未控制特应性皮炎儿童中的药代动力学、安全性和疗效。
J Eur Acad Dermatol Venereol. 2021 Feb;35(2):464-475. doi: 10.1111/jdv.16928. Epub 2020 Nov 8.
7
Successful and rapid clearance of severe, treatment-resistant atopic dermatitis with dupilumab in a 3-year-old.
Dermatol Ther. 2020 Nov;33(6):e14282. doi: 10.1111/dth.14282. Epub 2020 Sep 15.
8
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.度普利尤单抗联合外用皮质类固醇治疗 6 至 11 岁重度特应性皮炎儿童的疗效和安全性：一项随机、双盲、安慰剂对照的 3 期临床试验。
J Am Acad Dermatol. 2020 Nov;83(5):1282-1293. doi: 10.1016/j.jaad.2020.06.054. Epub 2020 Jun 20.
9
Atopic Dermatitis: Diagnosis and Treatment.特应性皮炎：诊断与治疗。
Am Fam Physician. 2020 May 15;101(10):590-598.
10
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.度普利尤单抗治疗青少年中重度特应性皮炎的疗效和安全性：一项 3 期随机临床试验。
JAMA Dermatol. 2020 Jan 1;156(1):44-56. doi: 10.1001/jamadermatol.2019.3336.